Want to join the conversation?
$COL 3Q15 10-Q: Total R&D expense increased $21MM YoverY. Total SG&A expenses increased $9MM YoverY. On Sept. 19, 2014 BoD authorized to repurchase an additional $500MM of common stock. Repurchased 919,800 shares at an average price of $96.06 per share. YTD 2015: Cash repurchases of stock up by $219MM to $330MM vs. $111MM repurchased YoverY.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.